Drugs / GRASPA
GRASPA
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Graspa | — | 2018-06-27 | europa.eu ↗ |
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04292743 | Dec 2020 → Jan 2023 | pancreatic ductal adenocarcinoma | Georgetown University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00723346 | Jan 2006 → Aug 2008 | acute lymphoblastic leukemia | ERYtech Pharma | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03267030 | Aug 2017 → Aug 2020 | acute lymphoblastic leukemia | Birgitte Klug Albertsen | Completed | No outcome recorded |
| Phase 2 | NCT02195180 | Jul 2014 → Feb 2017 | pancreatic adenocarcinoma | ERYtech Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01810705 | Feb 2013 → Nov 2017 | acute myeloid leukemia | ERYtech Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01523782 | Apr 2009 → Jan 2011 | acute lymphoblastic leukemia | ERYtech Pharma | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03674242 | Jun 2019 → Mar 2022 | triple-negative breast carcinoma | ERYtech Pharma | Terminated | No outcome recorded |
| Phase 2/3 | NCT01518517 | Dec 2009 → Sep 2014 | acute lymphoblastic leukemia | ERYtech Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03665441 | Sep 2018 → Aug 2021 | pancreatic ductal adenocarcinoma | ERYtech Pharma | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02197650 | — | acute lymphoblastic leukemia | ERYtech Pharma | No longer available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRASPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01518517 ↗ |
| Known as | ERY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02195180 ↗ |
| Known as | eryaspase | “The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65...” NCT01810705 ↗5“PURPOSE: Eryaspase is composed of l-asparaginase encapsulated in erythrocytes and has demonstrated significant efficacy in a randomized phase II trial.” PMID 32605910 ↗ Jun 2020 “eryaspase” NCT02197650 ↗ |
| Known as | erysapase | “Considering the promising results of ASNase for AML treatment and the better safety profile offered by GRASPA (L-aspariginase encapsulated in red blood cells, erysapase), a...” NCT01810705 ↗ |
| Known as | erythrocyte-encapsulated asparaginase | “This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic...” PMID 31760314 ↗ Nov 2019 |
| Modality | Protein / enzyme biologic | “Erythrocytes Encapsulating L-asparaginase (GRASPA)” NCT01518517 ↗ |
| Route | Intravenous | “eryaspase 100 U/kg intravenously on days 1 and 15” PMID 41187298 ↗ Nov 2025 |